Melbourne (Australia) and Berlin (Germany) – 18 May 2021. Telix has entered an exclusive commercial distribution agreement with Eckert & Ziegler for Telix’s prostate cancer imaging product Illuccix® for the German market.
Telix is pleased to announce that it has entered into an exclusive commercial distribution agreement with Berlin-based Eckert & Ziegler Strahlen und Medizintechnik AG (EZAG) for Telix’s prostate cancer imaging product Illuccix® (Kit for the preparation of 68Ga-PSMA-11 injection) for the German market.
Under the terms of the agreement, EZAG will be the exclusive commercial distributor of Illuccix® in Germany once the marketing authorisation has been granted for the product by the German health authorities, which is anticipated to occur in late 2021.
Telix Chief Executive Officer Dr. Christian Behrenbruch stated, “We are pleased to have entered this commercial distribution agreement with Eckert & Ziegler so that, subject to German regulatory approval, we will together be able to bring this highly anticipated imaging agent to German patients living with prostate cancer as efficiently as possible. Partnering with such a capable and patient-centric leader in nuclear medicine uniquely aligns with Telix’s mission of helping patients with cancer live longer, better quality lives.”
Member of the Executive Board of EZAG Dr. Harald Hasselmann added, “This commercial partnership with Telix will enable us to open the door to state-of-the-art PSMA imaging for the 68,000 men diagnosed with prostate cancer each year in Germany. Given that PSMA imaging represents the latest standard of care for prostate cancer imaging, having recently been included in European and U.S. clinical practice guidelines, we are delighted to be adding Illuccix® to our nuclear medicine portfolio and look forward to bringing this product to German patients in need.”
To read the full ASX disclosure please click here.
About Telix Pharmaceuticals (ASX: TLX)
Telix is a late-stage radiopharmaceutical company developing a broad portfolio of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix’s products address significant unmet medical needs in prostate, kidney, glioblastoma (brain) and hematologic (blood) cancers, as well as a range of immunologic and high value rare diseases.
The Company is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States, and is listed on the Australian Securities Exchange (ASX: TLX).
Telix’s lead product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. Food and Drug Administration (FDA) and has been granted Priority Review status by the Australian Therapeutic Goods Administration (TGA). Telix is also progressing marketing authorisation applications for Illuccix® in the European Union and Canada. None of Telix’s products have currently received a marketing authorisation in any jurisdiction. For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.